Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 20, 2009

FDA Clears Abbott’s Rheumatoid Arthritis Test

  • Abbott’s diagnostic test for rheumatoid arthritis has been approved by the FDA. The anti-CCP (antibody cyclic-citrulinated peptide) assay will be available on the company’s Architect immunoassay analyzers.

    Many patients with RA develop an immune response against proteins containing citrulline before they present symptoms of the disease, Abbott explains. Studies have shown that detecting the level of these antibodies earlier in the disease continuum in conjunction with other clinical information is critical to the early diagnosis of the disease, the firm adds.

    The assay was developed by Axis-Shield and will run on Abbott's Architect i1000SR and i2000SR systems. The anti-CCP assay is already approved and available on the Abbott Architect outside the U.S.

     



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »